Prosecution Insights
Last updated: November 12, 2026

Regenxbio Rs LLC

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Regenxbio Rs LLC currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, showing that each case is being handled independently by different personnel. This distribution suggests that the company's current patent efforts cover diverse technical sub-fields within the Biotechnology & Pharmaceuticals sector. The involvement of 2 distinct art units implies that the applications are being reviewed by different specialized groups. The lack of concentration in a single art unit may require the legal team to adapt to different procedural styles.

NGHI V NGUYEN is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending action. The alignment of 2 distinct examiners with 2 distinct art units suggests that the active prosecution spans different specialized groups within the technology area. With 2 pending office actions in total, the company's legal team must coordinate with 2 distinct examiners. This structure ensures that no single examiner's perspective dominates the company's current patent outcomes. Practitioners should focus on the 1 busiest examiner pending action while maintaining a flexible approach for the other distinct examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
Double-patenting + other1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NGUYEN, NGHI V 1 53.6% +50.8%
VYAS, KEYUR ANILKUMAR 1 49.4% +59.2%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18480172 TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) NGUYEN, NGHI V —
17260732 TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) VYAS, KEYUR ANILKUMAR —

Top Art Units

Art UnitApps
1653 1
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18480172 TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) NGUYEN, NGHI V 1653 §103 Non-Final OA — Pending Oct 03, 2023
17260732 TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) VYAS, KEYUR ANILKUMAR 1637 §103§112DP Non-Final OA — Pending Jan 15, 2021

Managing Regenxbio Rs LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Regenxbio Rs LLC have?

Regenxbio Rs LLC has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Regenxbio Rs LLC applications?

Nghi V Nguyen has the most, with 1 of Regenxbio Rs LLC's pending office actions.

What technology area are Regenxbio Rs LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month